190 related articles for article (PubMed ID: 30548257)
1. Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO).
Laribi K; Poulain S; Willems L; Merabet F; Le Calloch R; Eveillard JR; Herbaux C; Roos-Weil D; Chaoui D; Roussel X; Tricot S; Dupuis J; Dartigeas C; Bareau B; Bene MC; Baugier de Materre A; Leblond V
Br J Haematol; 2019 Jul; 186(1):146-149. PubMed ID: 30548257
[No Abstract] [Full Text] [Related]
2. Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
Chien HC; Morreall D; Patil V; Rasmussen KM; Yong CM; Li CY; Passey DG; Burningham Z; Sauer BC; Halwani AS
Am J Hematol; 2021 Jun; 96(6):E184-E187. PubMed ID: 33606890
[No Abstract] [Full Text] [Related]
3. Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2017 Feb; 92(2):209-217. PubMed ID: 28094456
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing.
Arulogun SO; Brian D; Goradia H; Cooney A; Menne T; Koo R; O'Neill AT; Vos JMI; Pratt G; Turner D; Marshall K; Manos K; Anderson C; Gavriatopoulou M; Kyriakou C; Kersten MJ; Minnema MC; Koutoumanou E; El-Sharkawi D; Linton K; Talaulikar D; McCarthy H; Bishton M; Follows G; Wechalekar A; D'Sa SP
Am J Hematol; 2023 May; 98(5):750-759. PubMed ID: 36866925
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.
Tedeschi A; Picardi P; Ferrero S; Benevolo G; Margiotta Casaluci G; Varettoni M; Baratè C; Motta M; Gini G; Goldaniga MC; Visco C; Zaja F; Belsito Petrizi V; Ravelli E; Gentile M; Urbano MA; Franceschetti S; Ghione P; Orsucci L; Frustaci AM; Gaidano G; Vitolo U; Morra E
Leuk Lymphoma; 2015; 56(9):2637-42. PubMed ID: 25651423
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous Infiltration due to Waldenström Macroglobulinemia.
Oscoz-Jaime S; Agulló-Pérez AD; Llanos-Chavarri C; Yanguas-Bayona JI
Actas Dermosifiliogr (Engl Ed); 2018; 109(1):75-78. PubMed ID: 28784233
[No Abstract] [Full Text] [Related]
7. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Talaulikar D; Tam CS; Joshua D; Ho JP; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Horvath N; Lee C; Zannettino A; Brown R; Augustson B; Jaksic W; Gibson J; Kalff A; Johnston A; Trotman J; Kalro A; Grigoriadis G; Ward C; Prince HM
Intern Med J; 2017 Jan; 47(1):35-49. PubMed ID: 28076910
[TBL] [Abstract][Full Text] [Related]
8. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
[TBL] [Abstract][Full Text] [Related]
9. Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia.
Treon SP; Hanzis C; Tripsas C; Ioakimidis L; Patterson CJ; Manning RJ; Sheehy P
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):133-5. PubMed ID: 21454214
[TBL] [Abstract][Full Text] [Related]
10. Rituximab plus cyclophosphamide and dexamethasone
Xiong W; Lyu R; Yu Y; Wang T; Yan Y; Wang Y; Liu W; An G; Deng S; Xu Y; Sui W; Huang W; Zou D; Wang J; Qiu L; Yi S
Haematologica; 2024 May; 109(5):1614-1618. PubMed ID: 38205507
[No Abstract] [Full Text] [Related]
11. Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance.
D'Alò F; Malafronte R; Piludu F; Bellesi S; Cuccaro A; Maiolo E; Modoni A; Leccisotti L; Macis G; Mores N; De Stefano V; Hohaus S
Br J Haematol; 2020 May; 189(4):e140-e144. PubMed ID: 32150646
[No Abstract] [Full Text] [Related]
12. Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
Laribi K; Poulain S; Willems L; Merabet F; Herbaux C; Roos-Weil D; Laribi de Materre I; Roussel X; Nudel M; Tricot S; Dupuis J; Le Calloch R; Bareau B; Leblond V
Br J Haematol; 2024 Mar; ():. PubMed ID: 38504454
[TBL] [Abstract][Full Text] [Related]
13. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia.
Castillo JJ; Gustine JN; Meid K; Dubeau TE; Severns P; Xu L; Yang G; Hunter ZR; Treon SP
Br J Haematol; 2018 Apr; 181(1):77-85. PubMed ID: 29468652
[TBL] [Abstract][Full Text] [Related]
14. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
Agathocleous A; Rohatiner A; Rule S; Hunter H; Kerr JP; Neeson SM; Matthews J; Strauss S; Montoto S; Johnson P; Radford J; Lister A
Br J Haematol; 2010 Nov; 151(4):346-53. PubMed ID: 20880120
[TBL] [Abstract][Full Text] [Related]
15. Waldenström macroglobulinemia: my way.
Gertz M
Leuk Lymphoma; 2013 Mar; 54(3):464-71. PubMed ID: 22860921
[TBL] [Abstract][Full Text] [Related]
16. Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis.
Kim JL; Gerrie AS; Savage KJ; Villa D; Scott D; Craig JW; Farinha P; Skinnider B; Slack G; Connors JM; Sehn LH; Venner C; Freeman CL
Leuk Lymphoma; 2024 Mar; 65(3):346-352. PubMed ID: 38156444
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.
Martínez-Calle N; Hartley S; Ahearne M; Kasenda B; Beech A; Knight H; Balotis C; Kennedy B; Wagner S; Dyer MJS; Smith D; McMillan AK; Miall F; Bishton M; Fox CP
Br J Haematol; 2019 Mar; 184(6):957-968. PubMed ID: 30548597
[TBL] [Abstract][Full Text] [Related]
18. Current therapy guidelines for Waldenstrom's macroglobulinaemia.
Kastritis E; Dimopoulos MA
Best Pract Res Clin Haematol; 2016 Jun; 29(2):194-205. PubMed ID: 27825466
[TBL] [Abstract][Full Text] [Related]
19. Acquired C1-inhibitor deficiency presenting with nephrotic syndrome.
Willows J; Wood K; Bourne H; Sayer JA
BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31300605
[TBL] [Abstract][Full Text] [Related]
20. Alkylating Agents in the Treatment of Waldenström Macroglobulinemia.
Buske C
Hematol Oncol Clin North Am; 2018 Oct; 32(5):821-827. PubMed ID: 30190020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]